Format

Send to

Choose Destination
Future Oncol. 2013 Nov;9(11):1727-32. doi: 10.2217/fon.13.164.

Effect of SAMITAL® in the treatment of chemotherapy-induced mucositis in adult oncohematological patients.

Author information

1
Department of Medicine, Hospital Clinico Regional de Valdivia, Valdivia, Chile.

Abstract

AIM:

We sought to evaluate the efficacy and safety of SAMITAL(®) (Indena SpA, Milan, Italy), a highly standardized botanical formulation, in reducing mucositis in patients undergoing treatment for hematological malignancies.

PATIENTS & METHODS:

In this observational, uncontrolled study, a total of 25 consecutively enrolled patients (19 males, aged 18-74 years) with chemotherapy-induced mucositis were compassionately treated orally with SAMITAL (three to four times per day) for 4-22 days per cycle.

RESULTS:

Patients demonstrated clinically relevant reductions in WHO mucositis grade with a reduction in pain, mucosal erosions, bleeding, dysphagia/feeding impairment and improvements in quality of life. SAMITAL was well tolerated and no local or systemic pharmacological, allergic, toxic or synergistic/antagonistic side effects were reported. Of note, SAMITAL also showed efficacy when administered prophylactically.

CONCLUSION:

These results add weight to previous experiences with SAMITAL. However, randomized, placebo-controlled clinical trials will need to confirm the suitability of SAMITAL for use in the treatment of mucositis.

PMID:
24156332
DOI:
10.2217/fon.13.164
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center